stocks logo

MDXG

MiMedx Group Inc
$
6.520
-0.15(-2.249%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.790
Open
6.710
VWAP
--
Vol
1.38M
Mkt Cap
963.02M
Low
6.465
Amount
--
EV/EBITDA(TTM)
16.68
Total Shares
147.60M
EV
897.40M
EV/OCF(TTM)
13.70
P/S(TTM)
2.82
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
102.56M
+10.39%
--
--
93.32M
+11.02%
--
--
90.79M
+4.11%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for MiMedx Group, Inc. (MDXG) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -5.23%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.21%
In Past 3 Month
Stock Price
Go Down
down Image
-5.23%
In Past 3 Month
5 Analyst Rating
up Image
80.21% Upside
Wall Street analysts forecast MDXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXG is 11.75 USD with a low forecast of 11.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image
80.21% Upside
Current: 6.520
sliders
Low
11.00
Averages
11.75
High
12.00
BTIG
maintain
2025-07-15
Reason
BTIG believes the selloff in shares of Organogenesis (ORGO) on the Centers for Medicare and Medicaid Services' proposed 2026 physician fee schedule "may be incorrect." Advanced wound care is likely the biggest news out of proposal as Medicare made a point to highlight how much costs have risen over the past few years, the analyst tells investors in a research note. BTIG believes that given the starting rate of $125.38, it expects to see significant pricing upside and downside for products under the proposed payment structure based on their reported average selling prices relative to the proposed rate. In Q4 of 2024, Organogenesis' Apligraf had an average selling price of $30.57, the analyst tells investors in a research note. If the starting rate is finalized, the product would see a 310.1% increase in price, notes BTIG. On the other hand, the firm says MiMedx's (MDXG) EpiFix and EpiCord will drop lose 21% and 49%, respectively, based on their Q4 prices. BTIG views last night's share selloff as "draconian," believing the CMS proposal may bring consolidation and a clean-up of the market. It keeps a Buy rating on Organogenesis. The stock in premarket trading is down 17% to $3.73.
Northland
Outperform
maintain
$12
2025-06-19
Reason
Northland attributes year-to-date weakness in MiMedx shares to concerns around CMS reimbursement in the private physician setting that represents about 25% of revenue and technical pressure following breaks below the 50- and 200-day moving averages. However, the firm argues that the "dislocation is unsupported" and views the recent pullback as one that "presents a compelling entry point for long-term investors." The firm maintains an Outperform rating and $12 price target on the shares.
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$13
2025-02-27
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$14 → $12
2024-08-01
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$11
2024-08-01
Reason

Valuation Metrics

The current forward P/E ratio for MiMedx Group Inc (MDXG.O) is 27.16, compared to its 5-year average forward P/E of 4.07. For a more detailed relative valuation and DCF analysis to assess MiMedx Group Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
4.07
Current PE
27.16
Overvalued PE
37.00
Undervalued PE
-28.86

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.00
Current EV/EBITDA
11.61
Overvalued EV/EBITDA
45.29
Undervalued EV/EBITDA
-27.30

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.74
Current PS
2.61
Overvalued PS
3.81
Undervalued PS
1.67

Financials

Annual
Quarterly
FY2025Q1
YoY :
+4.13%
88.21M
Total Revenue
FY2025Q1
YoY :
-39.17%
8.25M
Operating Profit
FY2025Q1
YoY :
-22.49%
7.02M
Net Income after Tax
FY2025Q1
YoY :
-16.67%
0.05
EPS - Diluted
FY2025Q1
YoY :
+1.22%
4.89M
Free Cash Flow
FY2025Q1
YoY :
-3.94%
81.12
Gross Profit Margin - %
FY2025Q1
YoY :
+79.35%
18.33
FCF Margin - %
FY2025Q1
YoY :
-25.61%
7.96
Net Margin - %
FY2025Q1
20.95
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.1M
USD
4
6-9
Months
526.3K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
1
1.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
8.1K
Volume
1
6-9
Months
76.3K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
6.7M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

MDXG News & Events

Events Timeline

2025-07-30 (ET)
2025-07-30
16:06:02
New
MiMedx sees FY25 revenue up low double-digits percent
select
2025-07-30
16:04:23
New
MiMedx reports Q2 EPS 6c, consensus 5c
select
2025-07-30
08:08:28
MiMedx announces strategic collaboration with Vaporox
select
Sign Up For More Events

News

8.0
07-28NASDAQ.COM
Notable Monday Option Activity: MDXG, GRPN, GTES
4.0
07-15Benzinga
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $11 Price Target
2.0
07-15Benzinga
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Sign Up For More News

FAQ

arrow icon

What is MiMedx Group Inc (MDXG) stock price today?

The current price of MDXG is 6.52 USD — it has decreased -2.25 % in the last trading day.

arrow icon

What is MiMedx Group Inc (MDXG)'s business?

arrow icon

What is the price predicton of MDXG Stock?

arrow icon

What is MiMedx Group Inc (MDXG)'s revenue for the last quarter?

arrow icon

What is MiMedx Group Inc (MDXG)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for MiMedx Group Inc (MDXG)'s fundamentals?

arrow icon

How many employees does MiMedx Group Inc (MDXG). have?

arrow icon

What is MiMedx Group Inc (MDXG) market cap?